
Quarterly report 2024-Q1
added 05-09-2024
Alpine Immune Sciences Net Debt 2011-2026 | ALPN
Net Debt can be roughly defined as financial liabilities that an entity classifies in the financing section together with the resources available to service those financial liabilities[1]
Net debt is the obligations that remain after deducting all assets and other liabilities from a company or individual. It represents the sum of debts that an organization or person must repay to their creditors or other parties.
Net debt can include various types of obligations such as loans, borrowings, lease liabilities, or credit card payments. It is important to note that net debt does not include current expenses or obligations such as payroll expenses or current bills.
Assessing net debt is an important financial indicator for evaluating the financial position of a company or individual. If net debt significantly exceeds assets, it may indicate financial difficulties and insolvency. In such cases, the company or individual may face difficulties in meeting their obligations and managing their finances.
Net debt can also be used to compare the financial stability of different companies. The lower the net debt relative to assets, the more stable and financially sound they are considered.
Overall, understanding net debt helps evaluate the financial soundness and ability of a company to meet their obligations. It is an important indicator that assists in making decisions about lending, investments, and financial management.
Annual Net Debt Alpine Immune Sciences
| 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|---|
| -63.9 M | -24.8 M | -11.2 M | -6.51 M | -2.97 M | -24.2 M | -25 M | -27.8 M | 14.2 M | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 14.2 M | -63.9 M | -19.1 M |
References
- Pizzo, M., Moscariello, N., & Vinciguerra, R. (2015). Market Incentives and Regulators' Activity Shaping Financial Information: An Analysis of the Net Debt Disclosure in Italy. International Journal of Business and Management, 10(1), 1.
Net Debt of other stocks in the Biotechnology industry
| Issuer | Net Debt | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Benitec Biopharma
BNTC
|
-1.92 M | $ 10.98 | -4.52 % | $ 452 M | ||
|
Ascendis Pharma A/S
ASND
|
-195 M | $ 221.88 | -0.87 % | $ 5 B | ||
|
MorphoSys AG
MOR
|
163 M | - | 2.43 % | $ 254 M | ||
|
Milestone Pharmaceuticals
MIST
|
-15.2 M | $ 1.36 | -20.0 % | $ 45.5 M | ||
|
Pharming Group N.V.
PHAR
|
-43.5 M | $ 15.36 | -0.71 % | $ 7.59 B | ||
|
I-Mab
IMAB
|
-1.06 B | - | - | $ 866 M | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
-402 M | - | - | $ 40.3 B | ||
|
Genfit SA
GNFT
|
2.27 M | - | 2.54 % | $ 160 B | ||
|
Inventiva S.A.
IVA
|
-95.6 M | $ 5.78 | -4.3 % | $ 138 M | ||
|
Biophytis SA
BPTS
|
-4.01 M | - | -13.47 % | $ 169 M | ||
|
Tiziana Life Sciences PLC
TLSA
|
-3.94 M | $ 1.21 | -3.97 % | $ 71.5 M | ||
|
Midatech Pharma plc
MTP
|
-6.17 M | - | -18.52 % | $ 27.3 M | ||
|
EyeGate Pharmaceuticals, Inc.
EYEG
|
-824 K | - | -1.52 % | $ 24.7 M | ||
|
Applied Genetic Technologies Corporation
AGTC
|
-36 M | - | - | $ 26.5 M | ||
|
PainReform Ltd.
PRFX
|
-15.7 M | $ 2.28 | -0.44 % | $ 1.03 M | ||
|
ARCA biopharma
ABIO
|
-60.6 M | - | 1052.0 % | $ 415 M | ||
|
Aeterna Zentaris
AEZS
|
-65.1 M | - | 5.93 % | $ 314 M | ||
|
AgeX Therapeutics
AGE
|
12.6 M | - | -10.17 % | $ 12.2 K | ||
|
Acorda Therapeutics
ACOR
|
114 M | - | -24.86 % | $ 820 K | ||
|
Albireo Pharma
ALBO
|
-239 M | - | -0.23 % | $ 916 M | ||
|
Aileron Therapeutics
ALRN
|
-3.44 M | - | 10.36 % | $ 9.8 M | ||
|
Acasti Pharma
ACST
|
-27.4 M | - | 4.01 % | $ 150 M | ||
|
Институт стволовых клеток человека
ISKJ
|
246 M | - | - | - | ||
|
Assembly Biosciences
ASMB
|
-55.8 M | $ 28.46 | 3.45 % | $ 319 M | ||
|
Avenue Therapeutics
ATXI
|
-3.13 K | - | -52.27 % | $ 4.45 M | ||
|
Autolus Therapeutics plc
AUTL
|
-187 M | $ 1.37 | -4.2 % | $ 350 M | ||
|
Adverum Biotechnologies
ADVM
|
31.1 M | - | - | $ 86.2 M | ||
|
Acer Therapeutics
ACER
|
-2.08 M | - | 2.71 % | $ 14 M | ||
|
Advaxis
ADXS
|
3.42 M | - | -9.65 % | $ 45.9 M | ||
|
Axsome Therapeutics
AXSM
|
-205 M | $ 156.92 | -1.23 % | $ 7.81 B | ||
|
Ayala Pharmaceuticals
AYLA
|
-657 K | - | - | $ 7.46 M | ||
|
AbCellera Biologics
ABCL
|
14.7 M | $ 3.4 | -3.68 % | $ 1.02 B | ||
|
Atreca
BCEL
|
33.1 M | - | -11.76 % | $ 5.79 M | ||
|
BioDelivery Sciences International
BDSI
|
-33.1 M | - | -4.8 % | $ 255 M | ||
|
BeiGene, Ltd.
BGNE
|
-3.56 B | - | 0.49 % | $ 251 B | ||
|
BioMarin Pharmaceutical
BMRN
|
-1.3 B | $ 54.13 | -1.64 % | $ 10.4 B | ||
|
Calithera Biosciences
CALA
|
-56.5 M | - | -10.95 % | $ 876 K | ||
|
Cara Therapeutics
CARA
|
-9.78 M | - | -3.03 % | $ 260 M | ||
|
ChemoCentryx
CCXI
|
-42.5 M | - | - | $ 3.74 B | ||
|
Bellerophon Therapeutics
BLPH
|
-23.8 M | - | -74.18 % | $ 955 K | ||
|
Compugen Ltd.
CGEN
|
-5.05 M | $ 2.09 | -0.95 % | $ 195 M | ||
|
Coherus BioSciences
CHRS
|
-85.6 M | $ 1.52 | -5.59 % | $ 178 M | ||
|
Checkpoint Therapeutics
CKPT
|
-40.8 M | - | - | $ 169 M | ||
|
Clovis Oncology
CLVS
|
293 M | - | -7.23 % | $ 13 M | ||
|
Aeglea BioTherapeutics
AGLE
|
-30.2 M | - | - | $ 1.01 B | ||
|
CureVac N.V.
CVAC
|
-783 M | - | - | $ 867 M | ||
|
Burford Capital Limited
BUR
|
-135 M | $ 7.7 | -5.87 % | $ 1.29 B | ||
|
Corbus Pharmaceuticals Holdings
CRBP
|
263 K | $ 8.6 | -3.8 % | $ 115 M | ||
|
Curis
CRIS
|
-17 M | $ 0.77 | 1.89 % | $ 4.86 M | ||
|
Akero Therapeutics
AKRO
|
-340 M | - | - | $ 3.67 B |